IP Library Patent Application 19391504
Patent Application
App. No. 19/391,504

ENCAPSULATED CANNABINOID FORMULATIONS FOR TRANSDERMAL DELIVERY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/391,504
Abstract

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Claims (18)

1 - 27 . (canceled)

28 . A method for treating a subject, comprising:

topically administering a cannabinoid composition into the subject in a dose amount effective to treat the subject's symptoms;

wherein the cannabinoid composition comprises:

an oil phase composition comprising:

a cannabinoid preparation;

at least one non-ionic surfactant, wherein the non-ionic surfactant comprises a hydrophilic compartment and a hydrophobic compartment; and

at least one co-solvent;

a water phase composition comprising

water; and

a stabilizing agent;

wherein the oil phase composition and the water phase composition are mixed to form micelles within a microemulsion having uni-, bi-, or multi-lamellar structures; wherein said cannabinoid composition yields the cannabinoid preparation capable of having increased bioavailability when topically administered; and wherein the at least one non-ionic surfactant forms a self-assembling emulsion in a self-emulsifying drug delivery system.

29 . The method of claim 28 , wherein the cannabinoid composition suitable for topical application in the form of an ointment, a cream, an emulsion, a lotion, a paste, an unguent, a gel or a sunscreen comprising therapeutically effective amounts of the cannabinoid composition.

30 . The method of claim 28 , wherein said cannabinoid composition is incorporated into a patch comprising a patch reservoir backing film and an adhesive; wherein the patch reservoir is capable of operably containing the cannabinoid composition within the backing film, and is capable of operably affixing to skin via the adhesive for transdermal delivery of the cannabinoid composition.

31 . The method of claim 30 , wherein the cannabinoid compositions is capable of delivering a sustained, therapeutic dose of the cannabinoid preparation for at least 72 hours.

32 . The method of claim 30 , wherein the patch reservoir is a drug encased reservoir.

33 . The method of claim 30 , further comprising a membrane sealed to the patch reservoir backing film.

34 . The method of claim 30 , wherein the membrane is a rate-controlling membrane.

Assignments (1)
SECURITY INTEREST Recorded Mar 11, 2026
From: NUTRAE LLC
To: NEEDHAM BANK
Reel/Frame 074042/0522 →